1200 Brickell Avenue
Suite 1950 #1183
Miami, FL 32183
United States
786-432-9792
https://mirapharmaceuticals.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Erez Aminov | CEO & Chairman | 337.05k | N/A | 1978 |
Ms. Michelle Yanez M.B.A. | CFO, Secretary & Treasurer | 338.77k | N/A | 1972 |
Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor | N/A | N/A | N/A |
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
MIRA Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.